Search - tctmd.com

Displaying 1 - 20 of 38

Sort: Relevancy | Date

PCI Comparable to CABG in Left Main Coronary Disease: Meta-analysis

News Daily News

PCI Comparable to CABG in Left Main Coronary Disease: Meta-analysis

Michael O'Riordan

December 14, 2017

Dreams Dashed: Intravascular Therapy for MS Flops in Sham-Controlled Trial

News Daily News

Dreams Dashed: Intravascular Therapy for MS Flops in Sham-Controlled Trial

December 05, 2017

My Takeaways From TCT 2017: Show Up, Keep It Civil, and Bring Your Best Self

News Opinion Editor's Corner TCT 2017

My Takeaways From TCT 2017: Show Up, Keep It Civil, and Bring Your Best Self

November 22, 2017

Low-Dose Rivaroxaban Plus Aspirin Lowers Some Costs in COMPASS, but Full Economic Impact Unclear

News Conference News AHA 2017

Low-Dose Rivaroxaban Plus Aspirin Lowers Some Costs in COMPASS, but Full Economic Impact Unclear

November 14, 2017

Statins and Diabetes: Causal Link Reinforced in New Analysis

News Daily News

Statins and Diabetes: Causal Link Reinforced in New Analysis

Michael O'Riordan

October 25, 2017

TCT 2017: High Hopes in Denver for Complex PCI, Shorter DAPT Durations, TAVR Costs, and More

News Conference News TCT 2017

TCT 2017: High Hopes in Denver for Complex PCI, Shorter DAPT Durations, TAVR Costs, and More

October 20, 2017

Alirocumab Ban Reversed, New Trial Ordered in PCSK9 Patent Dispute

News Daily News

Alirocumab Ban Reversed, New Trial Ordered in PCSK9 Patent Dispute

Michael O'Riordan

October 10, 2017

COMPASS: All Signs Point to Big Impact in CAD and PAD, Experts Predict

News Features

COMPASS: All Signs Point to Big Impact in CAD and PAD, Experts Predict

September 15, 2017

CHANGE DAPT: Study Contests Benefit of Ticagrelor Over Clopidogrel After PCI in ACS

News Conference News ESC 2017

CHANGE DAPT: Study Contests Benefit of Ticagrelor Over Clopidogrel After PCI in ACS

August 30, 2017

Anacetrapib Finds (Modest) Success Where All Other CETP Inhibitors Failed

News Conference News ESC 2017

Anacetrapib Finds (Modest) Success Where All Other CETP Inhibitors Failed

Michael O'Riordan

August 29, 2017

News Industry News

RE-DUAL PCI™ Results Offer Favorable New Safety Data on Pradaxa®

August 28, 2017

VIVA: Could Population-Wide Screening Trial for AAA, PAD, and Hypertension Save Lives at Low Cost?

News Conference News ESC 2017

VIVA: Could Population-Wide Screening Trial for AAA, PAD, and Hypertension Save Lives at Low Cost?

August 28, 2017

European Societies Issue New Valvular Heart Disease Guidelines, With Important Shifts

News Conference News ESC 2017

European Societies Issue New Valvular Heart Disease Guidelines, With Important Shifts

August 27, 2017

COMPASS Charts New Course for Rivaroxaban in Stable Vascular Disease

News Conference News ESC 2017

COMPASS Charts New Course for Rivaroxaban in Stable Vascular Disease

August 27, 2017

CABG Appears Superior to PCI for Patients With Type 1 Diabetes, Multivessel Disease

News Conference News ESC 2017

CABG Appears Superior to PCI for Patients With Type 1 Diabetes, Multivessel Disease

August 26, 2017

Evolocumab Not Cost-Effective at Current List Price

News Daily News

Evolocumab Not Cost-Effective at Current List Price

Michael O'Riordan

August 23, 2017

TAVR in the US: Regional Variations in Numbers, Outcomes

News Daily News

TAVR in the US: Regional Variations in Numbers, Outcomes

Michael O'Riordan

August 22, 2017

Studies Supporting Device Modifications Weak, Often Based on Surrogate Endpoints

News Daily News

FDA Clearance of Modified Devices Relies Heavily on Weak Studies, Surrogate Endpoints

Michael O'Riordan

August 16, 2017

Money-Back Guarantee for Evolocumab Has Little Impact on Cost-Effectiveness

News Daily News

Money-Back Guarantee for Evolocumab Has Little Impact on Cost-Effectiveness

Michael O'Riordan

August 08, 2017

How SGLT2 Inhibitors Help the Heart: Biomarker Study Offers Clues

News Daily News

How SGLT2 Inhibitors Help the Heart: Biomarker Study Offers Clues

August 01, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.